Figure 3.
Mutated GLI3 and KIT D816V act synergistically. (A) Immunoblots of BMMCs from Gli3 WT or Gli3 Xt+/− mice stained with GLI3 antibody; relative quantification of the GLI3A/GLI3R ratio. (B) Proliferation of WBM from Gli3 WT and Gli3 Xt+/− mice and differentiation into MCs with mIL3 +/− mSCF. P-values were calculated at day 21. (C) Immunoblots of BMMCs in mIL3+mSCF, stained with P-AKT, AKT, and p21 antibodies. (D) Time-course of the proliferation of BMMCs after transduction with KIT D816V-GFP or KIT WT-GFP lentiviral vectors. (E) Proliferation of WBM from Gli3 WT and Gli3 Xt+/− mice and differentiation into MCs after transduction with KIT D816V-GFP or KIT WT-GFP vectors. Data are from 3 independent experiments. *P < .05; **P < .01; ***P < .001.

Mutated GLI3 and KIT D816V act synergistically. (A) Immunoblots of BMMCs from Gli3 WT or Gli3 Xt+/− mice stained with GLI3 antibody; relative quantification of the GLI3A/GLI3R ratio. (B) Proliferation of WBM from Gli3 WT and Gli3 Xt+/− mice and differentiation into MCs with mIL3 +/− mSCF. P-values were calculated at day 21. (C) Immunoblots of BMMCs in mIL3+mSCF, stained with P-AKT, AKT, and p21 antibodies. (D) Time-course of the proliferation of BMMCs after transduction with KIT D816V-GFP or KIT WT-GFP lentiviral vectors. (E) Proliferation of WBM from Gli3 WT and Gli3 Xt+/− mice and differentiation into MCs after transduction with KIT D816V-GFP or KIT WT-GFP vectors. Data are from 3 independent experiments. *P < .05; **P < .01; ***P < .001.

Close Modal
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal